Greenwich Rx, a compounding pharmacy in Tomball, Texas, United States, announced on 20 November 2026 a voluntary nationwide recall of certain compounded sterile injectable products because it cannot assure they are sterile. The notice was published the same day by the US Food and Drug Administration (FDA). The recalled items include compounded semaglutide and tirzepatide blends, NAD+ injections and a range of peptide injections.
Which products are being recalled?
The recall covers specific lots that are still within their beyond-use dates, according to the company announcement posted by the FDA. A product and lot list on the Greenwich Rx website names 31 products and reports 261 recalled lots.
The list includes four semaglutide preparations combined with B12, glycine or methylcobalamin, and four tirzepatide preparations combined with B12, glycine, L-carnitine or methylcobalamin. It also includes NAD+, glutathione, Lipo-B and Lipo-C injections, and peptide products such as BPC-157, TB-500, GHK-Cu, CJC-1295/Ipamorelin, sermorelin, tesamorelin and thymosin alpha-1, alone or in blends.
The products were dispensed nationwide between 10 August and 21 September 2026. The lots visible on the company's list carry beyond-use dates running into December 2026.
The recall also covers some products that Greenwich Rx compounded for another pharmacy, Clove Rx. The company said Clove Rx customers should check the list even if they have not received a notice directly.
Why is the pharmacy recalling them?
The concern is a possible lack of sterility assurance. Greenwich Rx said the issue came to light after an FDA inspection of the pharmacy and its own review of the affected products.
The company said it has found no evidence of contamination and is acting as a precaution. It said it has received no reports of adverse events linked to the recall. The recall is being carried out with the FDA's knowledge.
Why does sterility matter?
Injectable medicines are meant to be sterile. The recall notice warns that using a product that should be sterile but is not could lead to serious infections, which may be life-threatening.
Greenwich Rx describes itself in the notice as a 503A compounding pharmacy.
What should patients do?
The company has asked people to stop using any affected product immediately and discard it. Patients can compare the label on their medicine with the product, lot and date list on the company's website. Anyone who has had a problem that may be related to one of these products should contact a doctor or other healthcare provider.
Greenwich Rx said it is notifying affected customers by mail. Questions are being handled by the claims firm Sedgwick on 888-243-5547 or by email at GreenwichRx6588@sedgwick.com, Monday to Friday from 8 am to 5 pm Eastern Time. Side effects can be reported to the FDA's MedWatch programme online, by mail or by fax.
What is not yet known?
The recall notice does not say how many patients received the affected products or what the FDA inspection found. The FDA has not published separate findings on the pharmacy alongside the notice.
Photo source · Intropin (Mark Oniffrey), CC BY-SA 4.0



